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Abstract 
PRELIMINARY SAFETY EVALUATION OF 17-HYDROXYPROGESTERONE   
CAPROATE (17-OHPC) INTRAVAGINAL GEL IN PREGNANT RATS 
 
Nupur Chaphekar, MS 
 
University of Pittsburgh, 2019 
 
 
 
Preterm birth is defined as delivery before 37 weeks of gestation. The only current FDA 
approved treatment option for the prevention of preterm birth is a 250 mg weekly intramuscular 
injection of an oily formulation of 17-hydroxyprogesterone caproate (17-OHPC) sold under the 
trade name Makena®. This treatment strategy requires the subjects to make weekly hospital visits 
and in addition, pain at injection site is a common complaint. 17-OHPC has been shown to be 
effective only in 33% of women receiving the treatment. Recently, the FDA approved 17-OHPC 
in a subcutaneous auto injector device (Makena auto-injector). The auto-injector device offers 
some potential advantages, but patients still need to visit the hospital to receive the injection. The 
injection site pain continues to be a problem with the autoinjector. An alternate route which is safe 
and effective is needed to help overcome these limitations and benefit a larger proportion of the 
patient population. 
Studies from our laboratory have evaluated the pharmacokinetics of 17-OHPC after 
different routes of administration in rats. The oral route of administration is not practical due to a 
low bioavailability of 3%. Vaginal administration is a logical choice and we have developed a gel 
formulation for 17-OHPC for vaginal administration. In a preliminary unpublished study from our 
lab, we have shown the feasibility and safety of intravaginal administration of 17-OHPC in female  
non-pregnant rats and rabbits. The goal of the current study was to evaluate the safety of 17-OHPC 
intravaginal gel in pregnant rats.   
 v 
A gel formulation of 17-OHPC was administered intravaginally to adult female pregnant 
sprague dawley rats starting from day 10 of gestation. The treatment was continued until the day 
of delivery. After delivery, both rats and pups were euthanized. Blood and vital organs were 
collected from the mother for the estimation of 17-OHPC concentrations using LC-MS-MS and 
for histopathology. Pups were fixed in formalin and the histopathology was assessed. 
Repeated intravaginal application did not alter body weight gain in the mothers. After 
vaginal administration, 17-OHPC showed high local tissue levels at the site of application with 
undetectable levels in plasma in the mothers. There were no gross differences in histopathology 
between control and treated rats indicating no tissue damage at the site of application in the 
mothers. The weight of the pups from both the groups showed no statistically significant 
differences. There was no damage to any of the vital organs in the pups and there were no 
differences in the number of pups delivered in control or treated mothers.   This indicates that the 
intravaginal administration of 17-OHPC gel appears to be safe in pregnant rats and the pups 
delivered. Having established the safety, we plan to initiate a safety study in non-pregnant women 
before conducting a clinical study in pregnant women. 
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1.0 Introduction 
1.1 Preterm Birth and its significance  
The gestational length of a normal pregnancy is around 40 weeks and the babies born between 37-
42 weeks of gestation are termed full term. Preterm birth (PTB) is defined as delivery before 37 
weeks of gestation.  According to the recent World Health Organization statistics, approximately 
15 million babies are born preterm annually [1]. The preterm birth rate in the US peaked in 2006 
at 12.8% and reduced to 11.4% in 2013, but still remains very high [2] . 
Preterm birth is an issue of major concern since it is a leading cause of neonatal morbidity and 
mortality in the United States [3]. Children who are born prematurely have higher rates of cerebral 
palsy, sensory deficits, learning disabilities and respiratory illnesses compared with children born 
at term. Preterm infants often require admission to intensive care unit and have longer hospital 
stays compared to their term counterparts resulting in increased healthcare costs [4].Preterm birth 
is also associated with numerous long-term health impairments and adult-onset diseases such as 
hypertension, obesity, and diabetes. The cost of preterm birth in the United States is estimated to 
be $26 billion as of 2005[5]. 
1.2 Mechanisms of preterm birth 
Preterm birth is classified as spontaneous or indicated based on the obstetric precursors 
leading to delivery. Preterm premature rupture of membranes (PPROM) or preterm labor with 
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cervical dilation leads to spontaneous preterm birth. PPROM is the spontaneous rupture of 
membranes at less than 37 weeks of gestation and 1 hour before contractions [6].The reasons for 
indicated preterm birth include preeclampsia, fetal distress, intrauterine growth retardation, 
abruptio placentae and fetal death [7] . The precise mechanism of preterm birth is still unknown 
but there are a number of risk factors associated with preterm birth including general risk factors, 
obstetric history and pregnancy related factors [8].  
General Risk Factors  
The maternal risk factors leading to preterm birth are race, stress levels, social and economic 
background, age, family history of preterm birth [9]. Although the mechanism is unclear, women 
with a higher BMI have a greater risk of preterm delivery [10]. Maternal medical disorders such 
as thyroid disease, hypertension can lead to increased rates of preterm delivery [6]. Preterm birth 
is associated with periodontal disease although the association is not clear. It may be due to the 
transmission of the mouth bacteria into the vagina. The risk of preterm birth increases as the 
disease progresses in pregnancy [11]. Smoking can increase spontaneous preterm birth. Cigarette 
smoke has chemicals such as nicotine and carbon monoxide which are powerful vasoconstrictors 
and  may lead to placental damage and decreased uteroplacental blood flow [6].  
Obstetric History 
Women with a previous preterm delivery have a 2.5-fold greater risk of subsequent preterm birth. 
The risk of subsequent preterm birth is inversely related to the gestational age at previous preterm 
birth [6]. Women with a short cervix have a greater risk for preterm delivery. The risk is inversely 
proportional to the size of the cervix [8]. Cervical insufficiency is defined as recurrent second-
trimester fetal loss due to the inability of the cervix to maintain pregnancy [12] .Cervical 
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insufficiency due to congenital cervical weakness, surgery or trauma can result in a greater risk of 
preterm birth [6].  
Pregnancy Related Risk Factors  
Multi-fetal gestations carry a substantial risk of preterm delivery and are responsible for 15-20% 
of preterm births. Multiple pregnancy is more likely than singleton pregnancy to be associated with 
preterm birth [13]. Nearly 60% of the twins are born preterm. Uterine overdistension and PPROM 
is believed to be the cause for preterm births in multifetal gestation[6] .  
Intrauterine infection is a frequent and important mechanism and accounts for 25-40% of the 
preterm births. Microorganisms causing the infection are recognized by toll-like receptors which 
in turn elicit the release of proinflammatory cytokines and chemokines which stimulate the 
production of prostaglandins and some other inflammatory mediators and matrix degrading 
enzymes. Prostaglandins cause uterine contractility whereas degradation of extracellular matrix in 
fetal membranes leads to PPROM [6]. 
Bacterial vaginosis defined as a change in the microbial ecosystem of the vagina is associated with 
a 1.5 to 3.5-fold increase in the rate of preterm birth [6, 14].  Asymptomatic Bacteriuria which is 
persistent colonization of bacteria in the urinary tract in the absence of specific symptoms such as 
bacteriuria, is associated with increased risk of preterm delivery [8, 15]. Fetal fibronectin is a 
glycoprotein found in the amniotic membranes, decidua and cytotrophoblasts. Higher levels of 
fibronectin have been associated with increased risk of preterm birth [8, 16].   
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1.3 Interventions for prevention of preterm birth  
Treatment of Asymptomatic Bacteriuria 
Several physiological changes during pregnancy such as dilated ureters, enlarged renal pelvis, 
displacement of bladder, smooth muscle relaxation leading to decreased peristalsis of ureters and 
increased bladder capacity may facilitate ascent of bacteria from bladder to the kidney. Without 
treatment, asymptomatic bacteriuria may proceed to pyelonephritis which is responsible for 5% of 
preterm births [17]. A short course antibiotic treatment regimen might be helpful for this condition 
[18].  
Smoking Cessation  
Tobacco use is related to a wide range of adverse pregnancy outcomes such as intrauterine growth 
restriction, placental abruption, preterm premature rupture of membranes, low birth weight. 
Tobacco use is linked to 5% - 8% of PTBs. Smoking cessation in pregnancy can reduce the PTB 
rate by up to 31%. The physicians should provide proper advice and consult for women to quit 
smoking[12]. Reduction of smoking in early pregnancy reduced the risk of preterm birth to the 
level of risk observed in non-smokers[19].  
Transvaginal ultrasonography of the cervix 
Transvaginal ultrasound measurement is useful for predicting preterm birth. It is a diagnostic tool 
which is used as a predictor of preterm birth. Current recommendations include initial screening 
at 16 weeks and repeating every 2 weeks until 24 weeks gestation. Normal ultrasound findings 
may help prevent unnecessary treatment, including inpatient hospital admissions and tocolysis 
later in pregnancy[12]. 
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Cervical Insufficiency Treatment 
The cervix dilates and opens towards the end of pregnancy to facilitate childbirth. Cervical 
insufficiency may cause opening of the cervix early which may lead to preterm birth [20].  
Cervical cerclage is a medical procedure in which the doctor places a stitch around the cervix to 
keep it closed. The suture can be removed as the full-term data approaches or if any other medical 
indications arise[20]. Cerclage placement in women with singleton gestations and a short cervix 
is another evidence-based strategy to reduce recurrent preterm births [12]. 
Cervical pessary is a flexible silicone device which may be helpful in reducing cervical 
insufficiency possibly by relieving pressure on the cervix [8].  
Tocolytics  
Tocolytic drugs are used to prolong pregnancy in women with an acute risk of preterm birth. 
Tocolytic drugs do not reduce preterm birth, but delay delivery by about 48 hours [21]. 
Administration of calcium channel blockers and oxytocin receptor antagonists or beta agonists 
have been shown to prolong delivery but not prevent preterm birth [22-24].  
Progesterone Administration  
 
Progesterone supplementation has shown promising results in reducing preterm birth. 
Progesterone is responsible for maintaining uterine quiescence during pregnancy and labor is 
associated with decreased levels of progesterone and increased levels of estrogen [25]. 
Progesterone has been shown to be effective in reducing the rate of preterm birth in women with 
a short cervix  [26, 27]. The clinical trial conducted by Meis et al supported the use of 17-OHPC 
for prevention of preterm birth where a 33% reduction in preterm birth was observed in women 
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with a history of prior preterm birth taking weekly injections of 17-OHPC [28]. But, 17-OHPC 
was ineffective in certain conditions like multifetal gestation and short cervix syndrome [29-31]. 
1.4 17-OHPC and preterm birth 
17-alpha hydroxyprogesterone caproate (17-OHPC) is a synthetic progestogen which is 
synthesized by acetylation of 17-alpha hydroxyprogesterone with caproic acid in presence of 
toluene sulfonic acid. It is an agonist of the progesterone receptor which is the biological target of 
progestogens like progesterone [32]. The exact mechanism of action of 17-OHPC has not been 
characterized. It is a lipophilic drug and is highly protein bound in blood mainly to albumin [5].17-
OHPC was originally introduced clinically in 1956 under the trade name Delalutin®. It was used 
for the treatment of gynecological and obstetrical disorders such as abortion and early pregnancy 
loss.  
CYP3A4 is primarily involved in metabolism of 17-OHPC in adult hepatocytes and the fetal form 
of CYP3A4 (CYP3A7) is involved in metabolism of 17-OHPC in fetal hepatocytes [33]. The 
metabolism of 17-OHPC by hepatic microsomes of human and baboons suggested the formation 
of mono, di and tri hydroxylated derivatives of 17-OHPC. The metabolism of 17-OHPC by 
placental microsomes of human and baboons led to the formation of mono hydroxylated 
derivatives of 17-OHPC. The hydroxy groups are added either on the progesterone nucleus or the 
caproyl moiety [34]. The effect of 17-OHPC on hepatobiliary transporters in adult and female 
hepatocytes have identified the inhibition of ABCB11 but the inhibition was observed at higher 
concentrations indicating no adverse effects are likely at therapeutic levels [35]. 
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The FDA approved formulation used for the prevention of preterm birth in women who have had 
a prior preterm birth is a 250 mg intramuscular injection that is administered once a week [36]. 
The treatment typically starts from the 16th week of gestation and continues till the 37th week of 
gestation or delivery, whichever occurs earlier. Recently, a subcutaneous auto-injector has been 
developed for 17-OHPC administration in the back of the upper arm. It received FDA approval in 
February 2018 [37]. 
 
 
Figure 1: Structure of 17-OHPC [38] 
 
 
Figure 2: Structure of progesterone[39] 
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Figure 3:  Structure of 17-hydroxyprogesterone [40] 
 
1.4.1  Limitations with existing formulations  
Administration of 17-OHPC by intramuscular injections have shown only 33% clinical benefit in 
pregnant women. There is no clinical evidence to support the superiority of clinical efficiency of 
the auto-injector over the intramuscular injection. The intramuscular injection has certain 
drawbacks such as frequent hospital visits, needle pain and large variations in drug exposure as 
measured by trough plasma concentrations of 17-OHPC [37, 41, 42]. Hence, an alternate route of 
administration which is safe and effective is needed. 
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1.4.2  Plasma concentration versus tissue distribution of 17-OHPC after different routes  
Studies conducted by Shaik et al evaluated the pharmacokinetics of 17-OHPC after various routes 
of administration. 17-OHPC was administered via the intramuscular, intravenous and oral routes. 
Intravenous administration lead to an initial distribution phase followed by a slower disposition 
phase. An initial rapid absorption phase was seen after intramuscular administration of solution 
dosage form with plasma concentrations declining over time similar to an IV administration. 
Intramuscular administration of an oil formulation resulted in low and sustained concentrations in 
plasma over a prolonged time period. Plasma concentrations were undetectable after oral 
administration of 17-OHPC at 5 mg/kg and the bioavailability was estimated to be only 3% after 
a dose of 25 mg/kg [36]. These observations ruled out oral route for chronic administration of 17-
OHPC. Logically the next route explored was the vaginal route offering the primary advantage of 
ease of administration. The various vaginal drug delivery systems include suppositories, tablets, 
creams, gels, films and rings. Crinone® (progesterone), Metrogel® (metronidazole) and 
EstroGel® (estrogen) are some examples of marketed vaginal gels. 
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Figure 4:Plasma concentration versus time profile of 17-OHPC after different routes of administration [36] 
1.4.3   17-OHPC Vaginal Formulation  
The vaginal formulation developed for 17-OHPC should have the following desired 
characteristics- 
• Proper viscosity to avoid leakage from vagina 
• Proper bio-adhesive/mucoadhesive properties to increase contact time with vaginal 
tissue 
• Non-toxic and non-irritating 
• Compatible with vaginal microflora 
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• Less frequent administration  
• No disruption of innate protective factors 
• Ease of administration  
• High local exposure 
• Low systemic exposure [43] 
 
1.4.4  Objective of the present study 
17-OHPC gel was prepared in hydroxyethyl cellulose (HEC), replens and mucolox gel. 
Preliminary studies were performed in non-pregnant rats and rabbits and the safety of these 
formulations was established. Studies in non-pregnant rats showed highest levels of 17-OHPC in 
female reproductive organs after application of mucolox gel.  An 8% progesterone gel is used in 
the clinic for prevention of preterm birth in women with a short cervix. We anticipate that creating 
a high local exposure in female reproductive organs with 17-OHPC like progesterone may lead to 
a greater benefit and hence decided to conduct further studies with 8% mucolox gel.  The aim of 
the current study was to ensure safety in pregnant rats since it will be administered to pregnant 
women.  
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2.0 Materials and Methods  
2.1 Materials  
2.1.1  Chemicals  
17-OHPC and Mucolox base was purchased from Professional Compounding Centers of America 
(PCCA), Houston, TX. Formic acid, medroxyprogesterone acetate, ammonium acetate and LC-
MS/MS grade solvents of highest purity were purchased from Sigma Chemicals, St Louis, MO.  
2.1.2  Animals  
Eight adult pregnant female Sprague-Dawley (SD) rats were obtained from Charles River 
Laboratories, Inc (Wilmington, MA). All the procedures were performed in accordance with the 
protocol approved by the University of Pittsburgh’s Institutional Animal Care and Use Committee 
(IACUC) and were according to the Guide for the Care and Use of Laboratory animals (National 
Research Council, 1996, Washington, District of Columbia). The rats were housed in the animal 
facility and followed a 12 h light/ dark cycle. The rats were allowed free access to food and water 
ad libitum. 
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2.2 Methods 
2.2.1  Preparation of Vaginal Gel 
Table 1 : Formula for 17-OHPC vaginal gel formulation 
 
Mucolox base from PCCA is a base with a unique polymer network that combines the benefits of 
water solubility and enhanced mucoadhesion properties. Mucolox base is a viscous liquid [44]. 
The Versabase gel is a clear transparent gel that is added to the mucolox base to form the mucolox 
gel and also to enhance the mucoadhesion properties. 17-OHPC, PCCA mucolox base and PCCA 
versabase gel base were added to a mortar and mixed with a pestle to form a white opaque gel 
ensuring no lumps of particle were formed. The gel was mixed using a spatula before packaging. 
The gel was filled and sealed with parafilm in 1 ml syringes. The filled syringes were stored at 
room temperature till use. The blank gel consisted of a transparent gel of PCCA mucolox base and 
PCCA versabase mixed using a mortar and pestle and filled in 1 ml syringes. 
                                          17-OHPC 8% Gel (MucoloxTM/Versabase®) 
Ingredient Quantity (For 100 g) 
17-OHPC 8 g 
Base, PCCA Mucolox ™ 51.1 g 
Base, PCCA Versabase® Gel 49.9 g 
 14 
2.2.2  Experimental Groups  
The study included a total of 8 pregnant rats which were randomly assigned to two different groups 
consisting of 4 rats per group. The gestation period in these animals is typically 21-23 days and 
we wanted to ensure that the animals receive treatment for at least half of the gestational period 
similar to the current practice in humans. We started treatment in these animals on the 10th day of 
gestation. The control group of rats was administered only the blank mucolox gel for a period of 
10 days or until delivery whichever occurred earlier. The treatment group of rats were administered 
8% 17-OHPC in mucolox gel intravaginally for a period of 10 days or until delivery whichever 
occurred earlier. The mother and pups were sacrificed immediately after delivery. The mother was 
sacrificed, and blood and tissue samples were collected during the time of euthanasia and stored 
at -800C till the time of analysis. The pups were euthanized by carbon dioxide asphyxiation.  The 
pups were fixed in formalin before sectioning.   
2.2.2.1 Observations and Measurements 
All animals were observed at least once a day during the study period. Gross maternal body 
weights were recorded daily. A detailed visceral examination of mothers was conducted. The 
plasma, uterus, adipose and ovary tissues from mother were analyzed for 17-OHPC concentrations. 
Litters were assessed for number of implants, resorptions/ dead, normal and abnormal fetuses. A 
detailed visceral examination of the fetuses was conducted [45].  
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2.2.3   Sample Analysis 
The plasma and tissue concentrations of 17-OHPC were measured using a previously developed 
and validated LC-MS/MS method in the lab with minor modifications [36, 46]. Partial validation 
was performed for the assay method used in this study. 
2.2.3.1 Standards 
The internal standard used was Medroxyprogesterone acetate (MPA). Methanolic stock solutions 
for primary standards and working solution for internal standard were prepared. The working 
standards, quality controls and internal standard were stored at -200C [36]. 
2.2.3.2 Sample Preparation 
Plasma samples were processed using solid phase extraction (SPE) cartridges. One hundred µl of 
the plasma sample was mixed with 25 µl IS and 1 ml water. Oasis® HLB 1 cc cartridges were 
washed with 1 ml methanol followed by 1 ml water for preconditioning and then the entire plasma 
sample mixture was passed through the cartridge. The cartridges were then washed with 1 ml of 
95% water and 5% methanol and dried under vacuum. 17-OHPC and IS were collected in a glass 
tube by eluting with methanol and evaporated to dryness under stream of air. The resultant residue 
was reconstituted in 100 µl of 50% methanol and 20 µl was injected into the LC-MS-MS system 
[36].  
Fifty mg of adipose or 100 mg of uterus from the cervical end was homogenized in 4 volumes of 
distilled water respectively using Polytron homogenizer. To 100 µl of tissue homogenate, 25 µl 
internal standard solution and 500 µl or 300 µl methanol was added to adipose and uterus samples 
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respectively, vortexed for 30 seconds and centrifuged at 15000 rpm for 5 minutes. Twenty µl of 
resultant supernatant was injected into the LC-MS-MS system.  
Ten mg of ovary was homogenized in 9 volumes of distilled water using Polytron homogenizer. 
To 100 µl of tissue homogenate, 25 µl internal standard solution and 300 µl methanol were added, 
vortexed for 30 seconds and centrifuged at 15000 rpm for 5 minutes. Twenty µl of resultant 
supernatant was injected into the LC-MS-MS system.  
2.2.4  Chromatography and mass spectrometry conditions 
The chromatographic system used for analysis of 17-OHPC was equipped with a Waters 2795 
console (Waters Corporation, Milford, MA). The compounds were separated on a ACQUITY 
UPLC® BEH shield RP 18 1.7 µm analytical column. The column was maintained at a temperature 
of 400C. The mobile phases were [A] 5% methanol in water containing 2mM ammonium acetate 
and 0.1% formic acid and [B] 5% water in methanol containing 2mM ammonium acetate and 0.1% 
formic acid. The sample run time was 10 minutes. The flow rate was 0.3 ml/min with a gradient 
starting from 30% solution [B] to 95% [B] over 1 min which was held until 4.0 min. The flow 
returned to the initial condition of 30% [B] in 6.0 min. 
Analysis was performed on a Micromass Quattro Micro triple quadrupole mass spectrometer 
(Waters Corporation, Milford, MA) with positive electrospray ionization mode (+ESI) and 
multiple reaction monitoring (MRM). The MRM setting used for analyzing the concentrations of 
17-OHPC in plasma and tissues were: capillary voltage 3.5kV; source temperature 1000C; de 
solvation temperature 4500C; cone gas flow (l/h) 50; de solvation gas flow (l/h) 550. The LC, mass 
spectrometer and data collection was performed by Masslynx software version 4.1 (Waters 
Corporation, Milford, MA) [36]. 
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2.2.5  Statistical Analysis 
Results are presented as mean ± standard deviation (SD) or mean ± standard error of mean (SEM) 
in the figures. Unpaired t-test was used for comparing the means between different groups. 
Kruskal-Wallis test was used to compare median between two or more groups followed by Dunn’s 
post hoc analysis, with a cutoff of p-value <0.05 considered to be significant. Statistical analysis 
was conducted using GraphPad Prism 7.  
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3.0 Results 
3.1 Drug administration 
The control group received intravaginal administration of mucolox gel for a period of 10 days. The 
treatment group received 8% 17-OHPC in mucolox gel for a period of 10 days. Two hundred µl 
of gel was administered to the rats daily. Different applicators were used for administration of the 
gel to the two different groups of rats. 
3.2 Mass spectroscopic analysis 
The retention times for 17-OHPC and MPA were 7.4 and 6.2 min, respectively. The mass to charge 
transitions for these compounds were m/z 429.06 → 313.05 for 17-OHPC and m/z 387.21 → 
327.26 for MPA (IS) [33]. 
 
3.2.1  Plasma Assay Validation  
Linearity 
The ratio of mean peak area of 17-OHPC to the internal standard was linearly related to the 
 
concentration of 17-OHPC in the concentration range of 5-1000 ng/ml. 
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Figure 5:Standard curve of 17-OHPC in rat plasma, showing linearity over a concentration range of  5-1000 
ng/ml 
Precision and accuracy 
Inter-day and intra-day coefficients of variation (CV) were within acceptable limits according to 
the guidance on bioanalytical method validation which is less than 15% for nominal concentrations 
and less than 20% for the lower limit of quantification (LLOQ). 
Table 2: Intra-day and Inter-day accuracy and precision of 17-OHPC assay in rat plasma 
 
 
 
 
 
 
 
 
 
17-OHPC Added concentration (ng/ml) 
15 100 900 
Intra-day assay  
21.8 ± 0.8 
 
125.7 ± 1.6 
 
978.5 ± 10.8 Mean ± S.D 
CV (%) 3.6 1.3 1.1 
Inter-day assay  
15.6 ± 0.4 
 
97.2 ± 12.1 
 
883.8 ± 29.2 Mean ± S.D 
CV (%) 2.1 12.4 3.3 
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Recovery 
Recovery was determined by comparing the peak areas of plasma samples spiked with 17-OHPC 
and fixed concentration of internal standard prior to extraction to the non-extracted standard 
analyte methanolic solutions. The recovery was > 97%. 
 
Ion Suppression 
Ion suppression was calculated by dividing the peak areas of blank extracted plasma samples 
spiked with 17-OHPC and fixed concentration of internal standard after extraction with non-
extracted standard analyte methanolic solutions at the same nominal concentration. The ion 
suppression was <18%. 
 
Table 3: Recovery and ion suppression recovery of 17-OHPC in rat plasma 
 
 
 
 
3.2.2  Adipose Assay Validation 
Linearity 
The ratio of mean peak area of 17-OHPC to the internal standard was linearly related to the 
 
EXTRACTION RECOVERY (%) ION SUPPRESSION RECOVERY 
(%) 
Concentration 
(ng/ml) 
Mean Concentration 
(ng/ml) 
Mean ± S.D. 
15 98 15 >100 
45 >100  45 99 
90 >100 90 83 
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concentration of 17-OHPC in concentration range of 5-500 ng/ml. 
 
 
 
 
Figure 6: Standard curve of 17-OHPC in rat adipose tissue, showing linearity over a concentration range of  
5-500 ng/ml 
 
Precision and accuracy 
Inter-day and intra-day coefficients of variation (CV) were within acceptable limits according to 
the guidance on bioanalytical method validation which is less than 15% for nominal concentrations 
and less than 20% for the lower limit of quantification (LLOQ). 
Table 4: :    Intra-day and Inter-day accuracy and precision of 17-OHPC assay in rat adipose tissue 
17-OHPC Added concentration (ng/ml) 
15 90 450 
Intra-day assay  
12.5 ± 1.9 
 
122.3 ± 9.3 
 
523.9 ± 110.8 Mean ± S.D 
CV (%) 15.2 7.6 21.1 
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Recovery 
Recovery was determined by comparing the peak areas of adipose tissue samples spiked with 17-
OHPC and fixed concentration of internal standard prior to extraction to the non-extracted standard 
analyte methanolic solutions. The recovery was > 30%. 
 
Ion Suppression 
Ion suppression was calculated by dividing the peak areas of blank extracted adipose tissue 
spiked with 17-OHPC and fixed concentration of internal standard after extraction with non-
extracted standard analyte methanolic solutions at the same nominal concentration. The ion 
suppression was < 1% 
 
Table 5: Recovery and ion suppression recovery for 17-OHPC in rat adipose tissue 
 
 
 
 
 
 
 
 
Inter-day assay  
17.0 ± 1.9 
 
77.1 ± 8.0 
 
439.9 ± 35.9 Mean ± S.D 
CV (%) 11 10.5 8.1 
EXTRACTION RECOVERY (%) ION SUPPRESSION RECOVERY 
(%) 
Concentration 
(ng/ml) 
Mean Concentration 
(ng/ml) 
Mean ± S.D. 
15 58 15 >100 
90 37 90 >100 
450 46 450 99 
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3.2.3  Uterus Assay Validation 
Linearity 
The ratio of mean peak area of 17-OHPC to the internal standard was linearly related to the 
 
concentration of 17-OHPC in concentration range of 5-500 ng/ml. 
 
 
Figure 7:Standard curve of 17-OHPC in rat uterus tissue, showing linearity over a concentration range of  5-
500 ng/ml 
 
 
Precision and accuracy 
Inter-day and intra-day coefficients of variation (CV) were within acceptable limits according to 
the guidance on bioanalytical method validation which is less than 15% for nominal concentrations 
and less than 20% for the lower limit of quantification (LLOQ). 
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Table 6: Intra-day and Inter-day accuracy and precision of 17-OHPC assay in rat uterus tissue 
 
 
 
 
 
 
 
 
 
 
Recovery 
Recovery was determined by comparing the peak areas of uterus tissue samples spiked with 17-
OHPC and fixed concentration of internal standard prior to extraction to the non-extracted standard 
analyte methanolic solutions. The recovery was > 70%. 
 
Ion Suppression 
Ion suppression was calculated by dividing the peak areas of blank extracted uterus tissue samples 
spiked with 17-OHPC and fixed concentration of internal standard after extraction with non-
extracted standard analyte methanolic solutions at the same nominal concentration. Ion 
suppression was <26%. 
 
17-OHPC 
Added concentration (ng/ml) 
15 90 450 
Intra-day assay 
14.7 ± 1.8 85.9 ± 7.9 473 ± 16.7 Mean ± S.D 
CV (%) 12.9 9.2 3.5 
Inter-day assay 
15.5 ± 2.0 85.7 ± 6.3 449.2 ± 40.7 Mean ± S.D 
CV (%) 13.4 7.3 9.0 
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Table 7: Recovery and ion suppression recovery for 17-OHPC in rat uterus tissue 
 
 
 
 
 
 
 
 
 
3.2.4  Ovary Assay Validation 
Linearity 
The ratio of mean peak area of 17-OHPC to the internal standard was linearly related to the 
 
concentration of 17-OHPC in concentration range of 5-500 ng/ml. 
 
 
EXTRACTION RECOVERY (%) ION SUPPRESSION RECOVERY 
(%) 
Concentration 
(ng/ml) 
Mean ± S.D. Concentration 
(ng/ml) 
Mean 
15 84 15 74 
100 71 100 76 
900 82 900 82 
 26 
 
Figure 8:Standard curve of 17-OHPC in rat ovary tissue, showing linearity over a concentration range of  5-
500 ng/ml 
Precision and accuracy 
Inter-day and intra-day coefficients of variation (CV) were within acceptable limits according to 
the guidance on bioanalytical method validation which is less than 15% for nominal concentrations 
and less than 20% for the lower limit of quantification (LLOQ). 
Table 8: Intra-day and Inter-day accuracy and precision of 17-OHPC assay in rat ovary tissue 
 
 
 
 
 
 
 
 
 
17-OHPC 
Added concentration (ng/ml) 
15 90 450 
Intra-day assay 
14.9 ± 1.7 86 ± 10.2 432.5 ± 60.7 Mean ± S.D 
CV (%) 11.4 11.9 14.0 
Inter-day assay 
14.46 ± 1.8 83.63 ± 8.2 464.7 ± 71.9 Mean ± S.D 
CV (%) 12.1 9.8 15.4 
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Recovery 
Recovery was determined by comparing the peak areas of ovary tissue samples spiked with 17-
OHPC and fixed concentration of internal standard prior to extraction to the non-extracted standard 
analyte methanolic solutions. The recovery was > 70%. 
 
Ion Suppression 
Ion suppression was calculated by dividing the peak areas of uterus tissue samples spiked with 
17-OHPC and fixed concentration of internal standard after extraction with non-extracted 
standard analyte methanolic solutions at the same nominal concentration.  There was no ion 
suppression observed. 
 
Table 9: Recovery and ion suppression recovery for 17-OHPC in rat ovary 
 
 
 
 
 
 
 
 
 
 
EXTRACTION RECOVERY (%) ION SUPPRESSION RECOVERY 
(%) 
Concentration 
(ng/ml) 
Mean  Concentration 
(ng/ml) 
Mean 
15 99 15 >100 
90 89 90 >100 
450 73 450 >100 
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3.3 Maternal Body Weights 
Repeated application of 17-OHPC intravaginal gel did not alter the body weight gain in rats. There 
was no difference in maternal body weights between the control and treated groups. 
 
Figure 9:Maternal Body weights of rats receiving vehicle gel or gel with 17-OHPC 
3.4 Maternal Plasma and Tissue Sample Analysis  
The plasma and tissue samples from the 4 rats in treatment group were analyzed using LC-MS-
MS. The plasma levels were below limit of detection of 1 ng/ml. 17-OHPC levels in ovary were 
below limit of detection of 1 ng/ml. Significant levels of 17-OHPC were seen in the adipose and 
uterus tissue. The results are presented as mean ± SD.  
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Figure 10:17-OHPC levels in adipose and uterus tissues of mothers receiving 17-OHPC gel 
3.5 Maternal Tissue Histopathology 
The tissues were scored for epithelial thinning, erosion, exudate, leukocyte infiltration, single-cell 
necrosis, single-cell vacuolation and luminal blood on a scale of 0 to 4 where 0 stands for no injury 
and 4 stands for a marked injury. There were no major differences in histopathology scoring 
between the control and treated groups.  
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Figure 11:Histopathology of tissues from mother (postpartum) indicating no difference between vehicle gel 
and gel with 17-OHPC 
 
3.6 Litter Size 
The litter size was similar among both the groups with an average litter size of 11 in the control 
group and 10 in the treated group. An unpaired t-test with Welch’s correction was used to check 
for significance and a p-value of 0.8676 (where p<0.05 is significant) was obtained indicating no 
significance difference between the groups. There was one dead pup in the control group. The 
results are presented as mean ± SD.  
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Figure 12:Litter size in control and 17-OHPC treated groups are not different 
3.7 Weight of the pups 
An unpaired t-test with Welch’s correction was used to check for significance where a p-value 
<0.05 was considered to be significant. The mean weight of the litter from the control group was 
3.85 and that of the treated group was 3.62. The weight of the litters from the control and treated 
groups was not significantly different with a p-value of 0.0708 . The results are presented as mean 
± SD.  
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Figure 13:Weight  of pups from both control and 17-OHPC treated group are not different 
3.8 Histology of pups  
The brain, lungs, heart, liver and gonads from the fetuses were examined for visceral 
malformations and scored on a scale of 0 to 4.  Zero stands for no injury and 4 stands for a marked 
injury.  No significant findings were seen indicating no injury. 
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Table 10: Histopathology of vital organs of pups 
 
 
 
 
 
 
 
 Control Treated 
 Dam1 
(n=12) 
Dam2 
(n=13) 
Dam3 
(n=9) 
Dam4 
(n=11) 
Dam1 
(n=12) 
Dam2 
(n=8) 
Dam3 
(n=12) 
Dam4 
(n=11) 
Brain 0     0                    0                0 0     0                    0                    0                
Lungs 0 0  0 0  0     0                    0                    0                
Heart 0 0 0 0 0 0     0                    0                
Liver 0 0 0  0 0     0                    0                    0                
Kidney 0 0 0 2 (n=1) 
0(n=10) 
0     0                    0                    0                
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4.0 Discussion  
Studies evaluating the pharmacokinetics of 17-OHPC in rats after different routes of 
administration ruled out the oral route since it exhibited poor bioavailability. This may be due to 
poor absorption, efflux or metabolism of 17-OHPC in the gut. Hence, the next route explored was 
the vaginal route.  
 
 
Figure 14: Tissue levels after administration of different 17-OHPC gels 
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The objective of the current study was to evaluate the safety of 17-OHPC vaginal gel in pregnant 
rats since preliminary data from our lab has shown that the 17-OHPC intravaginal gel does not 
cause any toxicity in non-pregnant rats and rabbits. This is the first study to evaluate the safety of 
intravaginal administration of 17-OHPC which is the only drug available for the prevention of 
preterm delivery. 
Previously, 17-OHPC vaginal gel was prepared in three bases viz. HEC, replens and mucolox. 
Short-term safety studies have been done with these gels in non-pregnant rats and rabbits and 
safety has been established. Replens gel had problems with leakage in the rabbits and we 
anticipated that this may lead to non-uniform dosage and hence decided to use HEC and mucolox 
gel for further studies.  
A 8 % progesterone gel (Crinone®) is used in the clinic for prevention of preterm birth in women 
with short cervix. Since the mechanism and site of action of 17-OHPC is still unknown we 
anticipate that creating a high local exposure like progesterone near the site of application may 
lead to a greater benefit. Hence, we decided to conduct further studies with mucolox base since it 
showed the highest concentrations of 17-OHPC near the site of application in the uterus and 
surrounding adipose tissue.  We decided to use a 8% gel of 17-OHPC similar to the clinically used 
progesterone gel. 
As shown in figure 10, mucolox gel showed highest release in the uterus and surrounding adipose 
tissue. Kruskal-Wallis test with multiple comparisons was used to compare 17-OHPC 
concentrations in uterus and adipose tissues from different gels at a p-value of <0.05 being 
significant. The results are presented as mean ± SEM. 17-OHPC concentrations in adipose were 
significantly different between the replens and mucolox gel (p-value of 0.0324), but not 
significantly different between the other groups (p-value > 0.99). 17-OHPC concentrations in the 
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uterus were not significantly different between the gels (p-value of >0.99).  17-OHPC levels in the 
plasma and ovary were below the limits of detection of 1 ng/ml. 
Preliminary unpublished data from the lab has established that the mucolox gel with 8% 17-OHPC 
is stable for at least a period of 6 months. The histopathology assessment of vital organs from the 
mother indicated that the intravaginal application of 17-OHPC causes no damage to the tissues 
from the mothers. No toxicity was seen in vital organs of the pups from control and treated 
mothers. 17-OHPC intravaginal gel is safe in pups delivered to control as well as treated mothers. 
A high local exposure was seen in the uterus and surrounding adipose tissue. The 17-OHPC levels 
in the ovary were below limit of detection. No systemic exposure was observed after intravaginal 
application of this gel.   In conclusion, the results indicate that 17-OHPC is not teratogenic in 
pregnant rats and does not cause any malformations in the delivered pups. Thus, a 8% 17-OHPC 
mucolox gel appears to be suitable for further evaluation. 
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5.0 Future Directions  
We are currently evaluating the in-vitro release of 17-OHPC from the developed gel. We have 
developed and validated a method of measuring 17-OHPC concentration in simulated vaginal fluid 
using HPLC-UV.  We plan to evaluate in-vitro release of 17-OHPC from the mucolox gel using 
the enhancer cell apparatus in simulated vaginal fluid. In-vitro release studies will give us an 
estimate about whether the drug needs to be dosed once a day or multiple times a day.  
One observation during this study was that histopathology scores of 2 or 3 were obtained for the 
vagina and uterus tissue with intravaginal application of the gel in the control group. Additional 
studies are needed to determine if these observations are due to the insertion of applicator into the 
vagina. Another comparison group that receive intravaginal progesterone can be added to compare 
regional distribution in uterus and cervix.  
Having established safety in pregnant rats, we plan to do a long-term safety evaluation in rabbits 
in the future since FDA requires safety studies to be conducted in at least two animal species (one 
rodent and one non-rodent). We plan to do a preliminary safety evaluation of the intravaginal gel 
in post-menopausal women in the future before conducting clinical studies in pregnant women. 
The ultimate goal of the project is to develop an alternate formulation to the currently available 
IM injection which is safe and effective and thereby improve outcomes in pregnancy.  
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Appendix A  
 
Figure 1: Medroxyprogesterone acetate  
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